Scott Lee, MD
Endocrinology, Diabetes & Metabolism · Loma Linda, CANPI 1902902042
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Mannkind Corporation accounts for 87.1% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2021 at $21,154 and has fallen 99.1% since, to $182 in 2025. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 128 payments — averaging $328.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mannkind Corporation$37K
- Medtronic$4K
- Novo Nordisk$453
- Bayer$295
- Dexcom, Inc.$167
- Sanofi-aventis U.S. LLC$92
- plus $121 from 3 others
Across 290 payments — averaging $1959.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$507K
- Novo Nordisk AS$61K
- Sequel Med Tech, LLC$250
What the payments were for
- Consulting fees$24,60059%
- Travel & lodging$13,74733%
- Food & beverage$2,4276%
- Education$2651%
- Gifts$9502%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mannkind Corporation | 64 | $36,589 |
| Medtronic(2 entities) | 19 | $4,273 |
| Novo Nordisk | 13 | $453 |
| Bayer | 5 | $295 |
| Dexcom, Inc. | 20 | $167 |
| Sanofi-aventis U.S. LLC | 4 | $92 |
| AstraZeneca | 1 | $86 |
| Cook Medical LLC | 1 | $18 |
| Nevro Corp. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AFREZZA$35,091
- Minimed 670G System$863
- Guardian Sensor 3$615
- Kerendia$243
- MINIMED 670G$175
- MINIMED 780G$152
How this compares
$41,990 in reported general payments places this provider in the 90th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 131 | $195,691 |
| MounjaroTirzepatide | 17 | $28,230 |
| JardianceEmpagliflozin | 30 | $26,734 |
| JanuviaSitagliptin Phosphate | 22 | $19,686 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $16,251 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 11 | $14,016 |
| Repatha SureclickEvolocumab | 14 | $13,818 |
| SynthroidLevothyroxine Sodium | 79 | $8,788 |
| NovologInsulin Aspart | 11 | $6,384 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $4,811 |
| Metformin Hcl | 33 | $3,101 |
| HumalogInsulin Lispro | 12 | $2,632 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 12 | $2,381 |
| Miglitol | 11 | $2,286 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 20 | $2,250 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $453 | $202,075142 claims |
| Sanofi-aventis U.S. LLCLantus | $92 | $89911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Loma Linda
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.